Avastin (Bevacizumab) Market Growth Through 2030 Creates New Strategic Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Avastin (Bevacizumab) Market Forecast: What Market Value Is Expected By 2030?
The market for avastin (bevacizumab) has experienced notable expansion over the past few years. Projections indicate it will increase from $7.82 million in 2025 to $8.43 million in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth has been driven by factors such as the clinical verification of VEGF inhibition, an escalating worldwide cancer incidence, extensive approvals for label expansions, widespread familiarity among oncologists, and early application in colorectal cancer treatments.
The avastin (bevacizumab) market is projected to experience robust expansion over the coming years, reaching a value of $11.27 million by 2030, driven by a compound annual growth rate (CAGR) of 7.5%. This anticipated growth during the forecast period is fueled by several key factors, including the rising availability of bevacizumab biosimilars, an expanding population of oncology patients, greater utilization in emerging markets, a growing demand for cost-effective biologic treatments, and the optimization of combination regimens. Among the prominent trends shaping this period are the sustained application of anti-angiogenic cancer therapies, the broadening of avastin’s use across diverse cancer types, an increasing trend of combining it with chemotherapy, its growing adoption for ophthalmic conditions, and a heightened focus on competition from biosimilars.
Download A Free Sample Report For Comprehensive Market Insights:
#Avastin (Bevacizumab) Market Growth Factors: Which Forces Are Supporting Market Expansion?
The growing incidence of cancer is anticipated to drive the avastin (bevacizumab) market forward in the coming period. Cancer is a broad term describing a set of disorders marked by the abnormal proliferation and dissemination of cells within the body. This rise in cancer cases is fueled by factors like an aging demographic, shifts in lifestyle habits, and more effective diagnostic tools. Avastin functions by inhibiting VEGF, thereby preventing the formation of blood vessels that deliver oxygen and nutrients to tumors, ultimately depriving them and hindering their growth. As an example, due to data published by the UK-based organization Macmillan Cancer Support in August 2024, over 3 million individuals in the United Kingdom were living with cancer in that year, with projections indicating an increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer is fueling the expansion of the avastin (bevacizumab) market.
An upward trend in healthcare spending is set to boost the avastin (bevacizumab) market in the foreseeable future. Healthcare spending encompasses all expenditures on medical goods and services, covering personal care, preventive measures, and public health initiatives, all designed to enhance health results over a defined timeframe. This surge in healthcare spending stems from an aging populace, the prevalence of chronic illnesses, cutting-edge medical innovations, elevated medication costs, ineffective reimbursement systems, and a heightened demand for medical services. Such expenditure advantages Avastin (bevacizumab) by improving its availability through broader insurance coverage, thereby fostering market growth and enabling wider patient utilization. For instance, per a May 2024 report from the Office for National Statistics, a UK governmental body, total healthcare expenditure saw a nominal increase of 5.6% between 2022 and 2023, contrasting with a 0.9% growth rate recorded in 2022. Thus, the rise in healthcare spending is accelerating the avastin (bevacizumab) market.
Avastin (Bevacizumab) Market Segment Performance And Strategic Opportunities
The avastin (bevacizumab) market covered in this report is segmented –
1) By Dosage: 100 Mg, 400 Mg
2) By Application: Non Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Cervical Cancer, Colorectal Cell Cancer, Ovarian Cancer, Proliferative Diabetic Retinopathy, Malignant Glioma, Neurofibromatosis, Pancreatic Cancer, Other Applications
3) By Distribution channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End User: Hospitals, Cancer Supportive Centers, Home Healthcare, Academic And Research Institutes, Other End Users
Avastin (Bevacizumab) Market Industry Trends: What Changes Are Reshaping Demand?
Major players within the Avastin (bevacizumab) market are placing significant emphasis on biosimilar expansion—particularly through high-profile bevacizumab biosimilars—as a means of securing a competitive edge. This concept of biosimilar proliferation describes the swift growth in both the number and availability of biosimilar medications entering the marketplace. For example, in December 2023, Bio Thera Solutions, a biopharmaceutical company headquartered in China, secured FDA approval for Avzivi (bevacizumab tnjn), a biosimilar of Avastin that demonstrates comparable efficacy, safety, and immunogenicity to the original product. Additionally, in July 2024, the European Medicines Agency (EMA) granted approval for BAT1706 / Avzivi across a range of oncology indications. While these advancements are promoting improved affordability and enhanced patient access, they simultaneously heighten pricing pressure on the innovator drug, pose a threat to its market dominance, and necessitate substantial production capabilities for any new players entering the field.
Avastin (Bevacizumab) Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the avastin (bevacizumab) market are Roche Holding AG
Access The Complete Avastin (Bevacizumab) Market Report:
Avastin (Bevacizumab) Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the avastin (bevacizumab) market in 2025. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
